U.S. markets close in 5 hours 43 minutes

  • S&P 500

    4,228.62
    -0.83 (-0.02%)
     

  • Dow 30

    32,926.55
    -75.83 (-0.23%)
     

  • Nasdaq

    13,094.62
    +35.16 (+0.27%)
     

  • Russell 2000

    1,718.57
    -8.58 (-0.50%)
     

  • Crude Oil

    86.84
    -2.39 (-2.68%)
     

  • Gold

    1,834.70
    -6.80 (-0.37%)
     

  • Silver

    21.14
    -0.24 (-1.13%)
     

  • EUR/USD

    1.0489
    +0.0020 (+0.19%)
     

  • 10-Yr Bond

    4.7680
    -0.0340 (-0.71%)
     

  • GBP/USD

    1.2117
    +0.0041 (+0.34%)
     

  • USD/JPY

    149.0740
    +0.0160 (+0.01%)
     

  • Bitcoin USD

    27,448.77
    +8.27 (+0.03%)
     

  • CMC Crypto 200

    584.46
    +0.30 (+0.05%)
     

  • FTSE 100

    7,421.18
    -48.98 (-0.66%)
     

  • Nikkei 225

    30,526.88
    -711.06 (-2.28%)
     

Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

Eledon Pharmaceuticals, Inc.
·1 min read
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc.

IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29, 2022 at 2:00 p.m. ET in New York City.

To register in advance for the fireside chat webcast, sign up here.

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com